Cupps Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cupps Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$36K	Sell	520 -19,859	-97%	-$1.27M	0.02%	156
2016 Q2	$996K	Sell	20,379 -45,810	-69%	-$2.96M	0.26%	121
2016 Q1	$4.19M	Buy	66,189 +12,917	+24%	+$845K	0.8%	46
2015 Q4	$5.98M	Buy	53,272 +13,130	+33%	+$1.31M	0.84%	47
2015 Q3	$3.87M	Sell	40,142 -10,732	-21%	-$1.23M	0.51%	63
2015 Q2	$5.21M	Sell	50,874 -91,760	-64%	-$7.12M	0.5%	78
2015 Q1	$8.86M	Buy	142,634 +85,885	+151%	+$4.77M	0.79%	51
2014 Q4	$2.49M	Sell	56,749 -55,171	-49%	-$2.53M	0.22%	107
2014 Q3	$6.33M	Buy	+111,920	New	+$5.63M	0.59%	66

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Cupps Capital Management's RARE Position: Q3 2016 in Review

Cupps Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 97% in Q3 2016, selling an estimated $1.27M and leaving 520 shares worth $36K. The position accounts for 0.02% of the portfolio, ranked #156.

Cupps Capital Management first reported a position in RARE in Q3 2014 and has held it in 9 quarters since. The position peaked at $8.86M in Q1 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q3 2016.

Cupps Capital Management held 520 shares of Ultragenyx Pharmaceutical worth $36K as of Q3 2016.
Cupps Capital Management sold 19,859 Ultragenyx Pharmaceutical shares in Q3 2016, an estimated $1.27M.
Ultragenyx Pharmaceutical made up 0.02% of Cupps Capital Management's portfolio in Q3 2016, its #156 holding.
Cupps Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and has held it in 9 quarters since.
Cupps Capital Management's Ultragenyx Pharmaceutical position peaked at $8.86M in Q1 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2016.

Based on Cupps Capital Management's 13F filing for Q3 2016, filed 11 Oct 2016.